Alirocumab is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Alirocumab enhances the liver's capacity to bind and clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby significantly reducing circulating levels of LDL-C. Additionally, Alirocumab modulates various inflammatory pathways, including the reduction of NLRP3 inflammasome activity and regulation of the Nrf2/HO-1, HMGB1/NF-??B, and Fractalkine/CX3CR1 signaling pathways. These mechanisms contribute to its therapeutic effects in improving atherosclerosis and reducing inflammation. Alirocumab is primarily used in research focused on lipid metabolism disorders, cardiovascular diseases, and inflammatory response modulation.
Alirocumab is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Alirocumab enhances the liver's capacity to bind and clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby significantly reducing circulating levels of LDL-C. Additionally, Alirocumab modulates various inflammatory pathways, including the reduction of NLRP3 inflammasome activity and regulation of the Nrf2/HO-1, HMGB1/NF-??B, and Fractalkine/CX3CR1 signaling pathways. These mechanisms contribute to its therapeutic effects in improving atherosclerosis and reducing inflammation. Alirocumab is primarily used in research focused on lipid metabolism disorders, cardiovascular diseases, and inflammatory response modulation.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
